Regeneron Pharmaceuticals
Tarrytown, United StatesFounded 1988
Regeneron Pharmaceuticals is a biotechnology company that invents, develops and commercializes life-transforming medicines. In April 2024, it launched Regeneron Ventures, a corporate venture capital arm with a $500 million commitment to invest in biopharmaceutical, healthcare, and health technology companies.
44% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (44% of deals). Average disclosed round size is $120.0M (across 9 rounds with reported amounts).
Portfolio
7
Fund Size
$500M
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 TriNetX | Series D | $200M | Apr 2026 |
| AArsenal Biosciences | Series C | $325M | Sep 2024 |
 DNAnexus | Series G | $100M | Jan 2020 |
| AAdicet | Series B | $80M | Oct 2019 |
| AAdicet Bio | Series B | $80M | Oct 2019 |
 Adicet Bio, Inc. | Unknown | $80M | Oct 2019 |
| AAdicet Bio | Series B | $80M | Jan 2019 |
| Adicet Bio, Inc. | Series B | $80M | Jan 2019 |
 Decibel Therapeutics | Series C | $55M | Jun 2018 |
Top Co-Investors
DSC Investment5 shared
Pontifax5 shared
Consensus Business Group5 shared
OrbiMed5 shared
Foresite Capital3 shared
GV2 shared
SR One1 shared
The Longevity Fund1 shared
Third Rock Ventures1 shared
Bessemer Venture Partners1 shared
Bristol Myers Squibb1 shared
Sixth Street Growth1 shared
ARCH Venture Partners1 shared
NVIDIA Corporation1 shared
aMoon1 shared
Johnson & Johnson Innovation1 shared
Northpond Ventures1 shared
First Round Capital1 shared
Perceptive Advisors1 shared
Last updated: 8 September 2026